(441 days)
OLPur™ H2H Hemodiafiltration Module, K112314
No
The description focuses on electro-mechanical and software control for generating and controlling substitution fluid, with no mention of AI or ML algorithms for decision-making or analysis.
Yes.
The device is used to perform hemodiafiltration treatment for patients with renal failure, which is a therapeutic intervention.
No
The device is described as an "electro-mechanical medical device designed to work in combination with a sterile single use HDF Infusion Set" to generate and control online substitution fluid for hemodiafiltration. Its purpose is to assist in treatment rather than to diagnose a condition.
No
The device description explicitly states it is an "electro-mechanical medical device" and includes components like a peristaltic pump, pressure sensor pods, and check valves, in addition to software control.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, or tissue) to provide information for the diagnosis, treatment, or prevention of disease.
- Device Function: The HDF Assist Module is a medical device used in conjunction with a hemodialysis machine to perform hemodiafiltration. It generates and controls substitution fluid from ultrapure dialysis fluid, which is then infused into the patient's extracorporeal circuit.
- Lack of Specimen Analysis: The device does not collect, prepare, or examine any specimens from the human body for diagnostic purposes. Its function is to facilitate a therapeutic treatment (hemodiafiltration) by preparing and delivering a fluid for infusion.
Therefore, the HDF Assist Module falls under the category of a therapeutic medical device, not an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
The HDF Assist Module is indicated for use, with the Fresenius 2008K2, and 2008T dialysis machines, for treatment of adult patients with acute or chronic renal failure or whenever hemodiafiltration is physician.
The HDF Assist Module works in conjunction with a qualified host high permeability (UF controlled) hemodialysis machine and its accessories (i.e., bloodlines, dialysate, concentrates, etc.), the HDF Assist Module accessories (HDF Infusion Set and Substitution Filter), appropriately purified water and ultrapure dialysate for hemodialysis, and a high permeability hemodialyzer / hemodiafilter (i.e., the OLPur™ MD 220 Hemodiafilter).
Product codes
KDI
Device Description
The HDF Assist Module is a software controlled; electro-mechanical medical device designed to work in combination with a sterile single use HDF Infusion Set (an accessory included in this submission) and a qualified host high permeability (UF controlled) hemodialysis machine, which produces ultrapure dialysis fluid. Upon installation the HDF Assist Module is connected to the host dialysis machine's IV Pole and plugged into a Standard 120VAC electrical mains power source.
To perform a hemodiafiltration treatment with the HDF Assist Module, the device is used in unison with the accessory sterile, single-use HDF Infusion Set to generate and control the online substitution fluid for hemodiafiltration from the ultrapure dialysis fluid of the host dialysis machine. The sterile HDF Infusion Set consists of an 0.25 m² ultrafilter, tubing including a peristatic pump segment, pressure sensor pods, and check valves.
The HDF Infusion Set is primed prior to treatment to remove air from the Set. The HDF Infusion Set is placed on the unit in preparation for each HDF treatment. A peristatic pump in the HDF Assist Module pumps a preset amount of ultrapure dialysis fluid produced by the host dialysis machine via the peristatic pump segment in the HDF Infusion Set. The dialysis fluid is drawn from an input dialysate Hansen T-connector and pumped through a sterile single use 0.25 m² ultrafilter in the HDF Infusion Set. The rest of the dialysis fluid flows outside of the fiber in the OLPur™ MD 220 Hemodiafilter as in conventional hemodialysis.
During priming and treatment, the ultrafilter in the HDF Infusion Set removes bacteria and endotoxins from the ultrapure dialysis fluid, thereby generating an injectable quality substitution (replacement) fluid of correct electrolyte composition. The ultrafiltered substitution fluid flows through tubing connected to the extracorporeal circuit where it is infused as part of the hemodiafiltration treatment at the MD220 Mid-Dilution port. The ultrafilter is 100% tested in a production integrity check during manufacture.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
adult patients
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
To assess the effects of the modified characteristics of the modified device and to demonstrate substantial equivalence with the predicate device, the following data assessed by scientific methods, performance and clinical data are provided:
Biocompatibility Testing: Performed according to ISO 10993-1, ISO 10993-5, ISO 10993-10, ISO 10993-11 and FDA Guidance "Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1", under the category of Externally Communicating Device; Blood Path, indirect; Prolonged (Category B).
Electrical Safety: Evaluated against requirements of FDA Consensus and International Standards, including AAMI ES60601-1:2005 +A1, CSA C22.2#60601-1:2014 Ed.3, IEC 60601-1-8:2003 Ed.1+A1, and IEC 60601-2-16:2018.
Electromagnetic Compatibility (EMC): Evaluated against requirements of FDA Consensus and International Standards, including IEC 60601-1-2 ed 4.0 (2014-02).
Microbiological Quality: Conformance with ANSI AAMI ISO 23500:2014 demonstrated by a multistage redundant system involving dialysis water treatment, qualified host dialysis machines (Fresenius 2008 K, 2008K2, and 2008T with Diasafe®/Diasafe®plus Options), and the sterile single use Nephros HDF Infusion set with a 0.25 m² ultrafilter capable of Log 10° reduction endotoxins and a Log 1011 reduction of bacteria.
Software Verification and Validation Testing: System level software verification testing per ANSI AAM IEC 62304:2006/A1:2016 demonstrated that the HDF Assist Module meets functional and performance software requirements.
System Performance Testing: Included verification of design inputs specific to HDF Assist Module including HDF Infusion Set in the following areas: Ultrafilter Disinfection and Reprocessing System Removal, Internal Pump Removal, Software Modification, Module Modification, Stand Removal, Filter and Cap Modification, Infusion Set and Substitution Filter Modification, Sensor and Regulator Modification.
Usability Testing: Evaluated against the requirements of FDA Consensus and International Standards for Usability (IEC 60601-1-6-Medical Electrical Equipment - Part 1-6: General Requirements For Basic Safety And Essential Performance - Collateral Standard Usability [IEC 60601-1-6:2010 Ed. 3 +A1]).
No animal or clinical studies were performed. The successful non-clinical testing demonstrated the safety and effectiveness of the HDF Assist Module.
Key Metrics
Not Found
Predicate Device(s)
OLPur™ H2H Hemodiafiltration Module, K112314
Reference Device(s)
Diasafe® (K944767), Diasafe®plus (K182367)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 876.5860 High permeability hemodialysis system.
(a)
Identification. A high permeability hemodialysis system is a device intended for use as an artificial kidney system for the treatment of patients with renal failure, fluid overload, or toxemic conditions by performing such therapies as hemodialysis, hemofiltration, hemoconcentration, and hemodiafiltration. Using a hemodialyzer with a semipermeable membrane that is more permeable to water than the semipermeable membrane of the conventional hemodialysis system (§ 876.5820), the high permeability hemodialysis system removes toxins or excess fluid from the patient's blood using the principles of convection (via a high ultrafiltration rate) and/or diffusion (via a concentration gradient in dialysate). During treatment, blood is circulated from the patient through the hemodialyzer's blood compartment, while the dialysate solution flows countercurrent through the dialysate compartment. In this process, toxins and/or fluid are transferred across the membrane from the blood to the dialysate compartment. The hemodialysis delivery machine controls and monitors the parameters related to this processing, including the rate at which blood and dialysate are pumped through the system, and the rate at which fluid is removed from the patient. The high permeability hemodialysis system consists of the following devices:(1) The hemodialyzer consists of a semipermeable membrane with an in vitro ultrafiltration coefficient (K
uf ) greater than 8 milliliters per hour per conventional millimeter of mercury, as measured with bovine or expired human blood, and is used with either an automated ultrafiltration controller or anther method of ultrafiltration control to prevent fluid imbalance.(2) The hemodialysis delivery machine is similar to the extracorporeal blood system and dialysate delivery system of the hemodialysis system and accessories (§ 876.5820), with the addition of an ultrafiltration controller and mechanisms that monitor and/or control such parameters as fluid balance, dialysate composition, and patient treatment parameters (e.g., blood pressure, hematocrit, urea, etc.).
(3) The high permeability hemodialysis system accessories include, but are not limited to, tubing lines and various treatment related monitors (e.g., dialysate pH, blood pressure, hematocrit, and blood recirculation monitors).
(b)
Classification. Class II. The special controls for this device are FDA's:(1) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Device—Part I: Evaluation and Testing,’ ”
(2) “Guidance for the Content of 510(k)s for Conventional and High Permeability Hemodialyzers,”
(3) “Guidance for Industry and CDRH Reviewers on the Content of Premarket Notifications for Hemodialysis Delivery Systems,”
(4) “Guidance for the Content of Premarket Notifications for Water Purification Components and Systems for Hemodialysis,” and
(5) “Guidance for Hemodialyzer Reuse Labeling.”
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
May 13, 2022
Nephros, Inc. Vashone R. Thomas VP of QA/RA 380 Lackawanna Place South Orange, New Jersey 07079
Re: K210575
Trade/Device Name: HDF Assist Mudule, HDF Infusion Set and Substitution Filter Regulation Number: 21 CFR 876.5860 Regulation Name: High permeability hemodialysis system Regulatory Class: II Product Code: KDI Dated: April 7, 2022 Received: April 13, 2022
Dear Vashone Thomas:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
1
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Gema Gonzalez Acting Assistant Director DHT3A: Division of Renal, Gastrointestinal, Obesity and Transplant Devices OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K210575
Device Name HDF Assist Module HDF Infusion Set & Substitution Filter
Indications for Use (Describe)
The HDF Assist Module is indicated for use, with the Fresenius 2008K2, and 2008T dialysis machines, for treatment of adult patients with acute or chronic renal failure or whenever hemodiafiltration is physician.
The HDF Assist Module works in conjunction with a qualified host high permeability (UF controlled) hemodialysis machine and its accessories (i.e., bloodlines, dialysate, concentrates, etc.), the HDF Assist Module accessories (HDF Infusion Set and Substitution Filter), appropriately purified water and ultrapure dialysate for hemodialysis, and a high permeability hemodialyzer / hemodiafilter (i.e., the OLPür™ MD 220 Hemodiafilter).
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the word "nephros" in a dark blue font. To the right of the word is a blue water droplet with a white outline. Below the water droplet are three curved lines that look like ripples in the water.
SECTION 05: 510(K) SUMMARY 5.
This 510(k) Summary is in accordance with the requirements of the Safe Medical Device Act (SMDA) of 1990. The content of this 510(k) Summary is provided in conformance with 21 CFR Part 807.92.
Submitter's Information:
| Submitter' Name & Company Address: | Nephros Inc.
380 Lackawanna Place
South Orange, NJ 07079
Establishment Registration # 3003337893 |
|------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Vashone R. Thomas; Vice President of Quality and Regulatory Affairs
380 Lackawanna Place
South Orange, NJ 07079 |
| Phone: | 201-345-0829 |
| Facsimile: | 201-343-5207 |
| Email: | vashone@nephros.com |
| Date Prepared: | May 13, 2022 |
Device Information:
| Trade Name: | HDF Assist Module, HDF Infusion Set
& Substitution Filter |
|------------------------|--------------------------------------------------------------|
| Regulation Name: | High Permeability Hemodialysis
System |
| Classification Number: | Class II per 21 CFR Part 876.5860 |
| Product Code | KDI |
| Classification Panel | Gastroenterology/Urology |
Predicate Information:
The predicate device for the HDF Assist Module is the OLPur™ H2H Hemodiafiltration Module, K112314, granted 04/27/2012.
Device Description:
The HDF Assist Module is a software controlled; electro-mechanical medical device designed to work in combination with a sterile single use HDF Infusion Set (an accessory included in this submission) and a qualified host high permeability (UF controlled) hemodialysis machine, which produces ultrapure dialysis fluid. Upon installation the HDF Assist Module is connected to the host dialysis machine's IV Pole and plugged into a Standard 120VAC electrical mains power source.
To perform a hemodiafiltration treatment with the HDF Assist Module, the device is used in unison with the accessory sterile, single-use HDF Infusion Set to generate and control the online substitution fluid for hemodiafiltration from the ultrapure dialysis fluid of the host dialysis machine. The sterile HDF Infusion Set consists of an 0.25 m² ultrafilter, tubing including a peristatic pump segment, pressure sensor pods, and check valves.
The HDF Infusion Set is primed prior to treatment to remove air from the Set. The HDF Infusion Set is placed on the unit in preparation for each HDF treatment. A peristatic pump in the HDF Assist Module pumps a preset amount of ultrapure dialysis fluid produced by the host dialysis machine via the peristatic pump segment in the HDF Infusion Set. The dialysis fluid is drawn from an input dialysate Hansen T-connector and pumped through a sterile
4
Image /page/4/Picture/0 description: The image shows the word "nephros" in a dark blue font. To the right of the word is a blue water droplet with a white swirl inside. Below the water droplet are three curved lines, which give the impression of ripples in the water.
single use 0.25 m² ultrafilter in the HDF Infusion Set. The rest of the dialysis fluid flows outside of the fiber in the OLPūr™ MD 220 Hemodiafilter as in conventional hemodialysis.
During priming and treatment, the ultrafilter in the HDF Infusion Set removes bacteria and endotoxins from the ultrapure dialysis fluid, thereby generating an injectable quality substitution (replacement) fluid of correct electrolyte composition. The ultrafiltered substitution fluid flows through tubing connected to the extracorporeal circuit where it is infused as part of the hemodiafiltration treatment at the MD220 Mid-Dilution port. The ultrafilter is 100% tested in a production integrity check during manufacture.
Indications for Use:
| Predicate | Modified Device | |
|---|---|---|
| OLPūr™ H2H Hemodiafiltration (HDF) Module | HDF Assist Module, HDF Infusion Set & | |
| Substitution Filter | ||
| Indications for | ||
| Use: | The OLPūr™ H2H Hemodiafiltration (HDF) Module | |
| is indicated for use, with an approved | ||
| dialysis machine, for treatment of patients with | ||
| acute or chronic renal failure or whenever | ||
| hemodiafiltration is prescribed by a physician. | The HDF Assist Module is indicated for use, | |
| with the Fresenius 2008K, 2008K2, and 2008T | ||
| dialysis machines, for treatment of adult | ||
| patients with acute or chronic renal failure or | ||
| whenever hemodiafiltration is prescribed by a | ||
| physician. | ||
| The OLPūr™ H2H Hemodiafiltration (HDF) Module | ||
| works in conjunction with a qualified | ||
| host high permeability (UF controlled) | ||
| hemodialysis machine and it's accessories (i.e., | ||
| bloodlines, dialysate, concentrates, etc.), the H2H | ||
| Module accessories (water and | ||
| substitution fluid filters infusion / rinse line, and | ||
| optional blood extension line), | ||
| appropriately purified water for hemodialysis, and | ||
| a high permeability hemodialyzer / | ||
| hemodiafilter (i.e., the OLPūr™ MD 220 | ||
| Hemodiafilter). | The HDF Assist Module works in conjunction | |
| with a qualified host high permeability (UF | ||
| controlled) hemodialysis machine and its | ||
| accessories (i.e., bloodlines, dialysate, | ||
| concentrates, etc.), the HDF Assist Module | ||
| accessories (HDF Infusion Set and Substitution | ||
| Filter), appropriately purified water and | ||
| ultrapure dialysate for hemodialysis, and a | ||
| high permeability hemodialyzer / | ||
| hemodiafilter (i.e., the OLPūr™ MD 220 | ||
| Hemodiafilter). |
Summary and Comparison of Technological Characteristics with Predicate Device:
The proposed HDF Assist Module and the predicate device (K112314) are substantially equivalent in the following technological characteristics:
- Design Features
- Electrical Safety
- . Electromagnetic Compatibility (EMC)
- Material Biocompatibility (Patient and Non-Patient Contact)
- Microbiological Quality (maximum allowable levels for total viable microbial count and endotoxins in the substitution fluid)
- Principle of Operation
- Software
- Standards (Electrical and electromagnetic safety, Water Purification and Hemodialysis Standards)
The performance testing completed on the proposed device to support the determination of substantial equivalence is summarized below and has been developed in accordance with appropriate FDA guidance
5
Image /page/5/Picture/0 description: The image shows the word "nephros" in a bold, sans-serif font. The word is in a dark blue color. To the right of the word is a stylized water droplet in a lighter blue color. Below the water droplet are three curved lines, suggesting ripples in the water.
documents and relevant standards. The HDF Assist Module has been modified to simplify the design and optimize performance.
The complete list of changes implemented and included in the HDF Assist Module are included in the summary of Non-clinical Performance data below.
Assessment of Non-Clinical Performance Data/Substantial Equivalence:
Safety and Effectiveness
To assess the effects of the modified characteristics of the modified device and to demonstrate substantial equivalence with the predicate device, the following data assessed by scientific methods, performance and clinical data are provided.
Biocompatibility Testing
Design updates to the module, infusion set, and substitution filter have been made to the predicate device and biocompatibility has been evaluated. Testing was performed according to ISO 10993-1, ISO 10993-5, ISO 10993-10, ISO 10993-11 and FDA Guidance "Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1", under the category of Externally Communicating Device; Blood Path, indirect; Prolonged (Category B).
Electrical Safety
The HDF Assist Module has been evaluated against the requirements of FDA Consensus and International Standards for Electrical Safety and other applicable standards by an independent ANSI Certified Testing Service company Interek Testing Services N.A. Inc. The applicable standards include:
- AAMI ES60601-1:2005 +A1 – Medical Electrical Equipment - Part 1: General Requirements for Basic Safety and Essential Performance
- . CSA C22.2#60601-1:2014 Ed.3 – Medical Electrical Equipment - Part 1: General Requirements For Basic Safety And Essential Performance
- IEC 60601-1-8 Medical Electrical Equipment - Part 1-8: General Requirements For Basic Safety And Essential Performance - Collateral Standard: General Requirements, Tests And Guidance For Alarm Systems In Medical Electrical Equipment And Medical Electrical Systems [IEC 60601-1-8:2003 Ed.1+A1]
- . IEC 60601-2-16:2018 - Medical electrical equipment Part 2-16: Particular requirements for the safety and essential performance of haemodiafiltration and haemofiltration equipment (Applicable Clauses)
Electromagnetic Compatibility (EMC)
The HDF Assist Module has been evaluated against the requirements of FDA Consensus and International Standards for EMC Compatibility by an independent ANSI Certified Testing Service company (Interek Testing Services N.A. Inc.) The applicable standards include:
- IEC 60601-1-2 ed 4.0 (2014-02) Medical electrical equipment – Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances -Requirements and tests (with EMC deviations per IEC 60601-2-16:2018)
Microbiological Quality
The microbiological quality of the substitution fluid as determined by the maximum allowable levels for total viable microbial count and endotoxins is in conformance with ANSI AAMI ISO 23500:2014 Guidance for the preparation and quality management of fluids for hemodialysis and related therapies. The microbiological
6
Image /page/6/Picture/0 description: The image shows the word "nephros" in a bold, sans-serif font. The word is in dark blue, and to the right of the word is a blue water droplet. Below the water droplet are three curved lines, which give the impression of ripples in the water.
quality of the substitution fluid produced by the HDF Assist Module is assured by a multistage redundant system.
-
- As required for standard hemodialysis, there must be a properly maintained dialysis water treatment system with reverse osmosis and other required components as determined by water analysis and the ISO 23500 standard. This produces maximum allowable levels for total viable microbial count and endotoxins in the water input to the dialysis machine of